CAR T-Cell Therapy: Progress and Prospects.

Area of Science:

• Immunology
• Gene Therapy
• Oncology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in targeted cancer immunotherapy.
• Early gene therapy approaches for enhancing antitumor immunity lacked specificity and efficacy compared to CAR T-cell technology.

Purpose of the Study:

• To review the historical development and iterative improvements in CAR vector design since the 1990s.
• To highlight emerging strategies in CAR vector engineering for future gene therapy applications.

Main Methods:

• Review of lentivirus-mediated transduction of T cells with CARs.
• Analysis of CAR T-cell engineering combining antibody gene sequences with T-cell receptor and activation domains.
• Examination of CD19-directed CAR T cells for B-cell malignancies.

Main Results:

• CAR T-cell therapy demonstrates widespread therapeutic efficacy in treating specific cancers, such as CD19-expressing B-cell malignancies.
• The engineering of CAR T cells provides a highly specific antitumor response through a single vector approach.

Conclusions:

• CAR T-cell therapy is a leading human gene therapy technique for cancer treatment.
• Ongoing advancements in CAR vector design promise to broaden the scope and impact of CAR T-cell therapy in the future.